Tiny Worms Lead Simon Fraser Researcher To Potential Anti-Cancer Drugs, Antibiotics

March 28, 1997

Simon Fraser University research on the use of microscopic worms to control insect pests has yielded unexpected results: natural chemicals--never seen before--with apparently potent capabilities as antibiotics and anti-cancer agents.

This surprising turn of events has led to one patent, five others pending and a spin-off company, says team leader Dr. John Webster of SFU's department of biological sciences.

Research on microscopic worms called nematodes led to the discovery. Scientists believe there are as many species of nematodes as there are insects. Virtually all are thin and worm-like; most are microscopic. In humans, they are known as roundworms.

Webster has spent 30 years researching nematodes and, in particular, how some species damage crops, while others kill insect pests.

When applied as insect-control agents, some nematodes act like hypodermic needles, injecting killer-bacteria into the host. Webster and his six-person interdisciplinary team have shown that these killer-bacteria create waste products which are toxic to fungi and other species of bacteria.

Intrigued by this development, the team--including Dr. Jianxong Li and Dr. Genhui Chen--proceeded to identify the chemical composition of some of these waste products and explore their potential uses as antibiotics and anti-cancer agents.

When mixed in a Petri dish with various types of human cancer cells including those associated with particular leukemias, prostate, lung and breast cancer, these waste products--dubbed "xenorxides"--have proven more effective than some traditional anti-cancer drugs in duplicate settings.

Related substances act as antibiotics. In test tube experiments they have proven effective in destroying the bacteria associated with tuberculosis and some highly infectious drug-resistant staphylococcus infections.

Scientists at the B.C. Cancer Agency are currently testing the xenorxides in rodents to assess their cancer-killing effectiveness in living organisms. Another organization is testing related substances as a drug treatment for tuberculosis.

The growing problem of drug-resistant bacterial strains lends added significance to the SFU research. "The chemical compositions of these substances are very different from those of existing drugs such as penicillin," says Webster. "Consequently, they may prove, one day, to be particularly potent medicinal weapons."

Nematodes are used locally to combat the black vine weevil which feeds off the valuable cranberry crop. Millions of nematodes are sprayed periodically onto cranberry fields as an ecologically benign control method.

It was in 1995, while investigating the impact such spraying had on the soil, that Webster's team zeroed in on the bacterial waste products. Finding some novel anti-microbial substances, they embarked on an entirely new research direction focusing on humans instead of insects.

Webster says these new substances now must prove themselves through a myriad of tests. Even the most optimistic scenario would require six to eight years of development before any human application could occur.

Funding for Webster's anti-cancer and antibiotic research has come from the federal Natural Sciences and Engineering Research Council, the National Research Council and the private sector.

Contact: Dr. John Webster, (604) 291-3336 or 291-4105 Ken Mennell, media/public relations, (604) 291-3929
-end-


Simon Fraser University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.